Pfizer and BioṆTech’ s Booster Receive the US FDA’s EUA for Adolescents
Shots:
- The US FDA has expanded the EUA of a booster dose of Pfizer-BioNTech COVID-19 vaccine to include children aged ≥12yrs. The dosage strength (30µg) of the booster dose is same as the dose approved in the primary series
- Additionally, the FDA action reduces time between completion of primary series and booster dose for all eligible individuals, and approves a third primary series dose for individuals aged 5-11yrs. with immunocompromise
- The US FDA previously approved booster dose in people aged ≥16yrs. and for ≥18yrs. of age who received other authorized COVID-19 vaccines
Ref: Pfizer | Image: The Wall Street Journal
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com